<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39334280</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-6511</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC pharmacology &amp; toxicology</Title><ISOAbbreviation>BMC Pharmacol Toxicol</ISOAbbreviation></Journal><ArticleTitle>Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.</ArticleTitle><Pagination><StartPage>71</StartPage><MedlinePgn>71</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">71</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40360-024-00790-2</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Tafamidis-associated adverse events (AEs) were investigated retrospectively by data mining the US Food and Drug Administration Adverse Event Reporting System (FAERS) to inform clinical safety.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data were gathered from the FAERS database, which spans the second quarter of 2019 to the fourth quarter of 2023. A total number of 8532 reports of Tafamidis-related adverse events were detected after evaluating 8,432,351 data. Disproportionality analyses were used to quantify the signal and assess the significance of Tafamidis-associated AEs using four algorithms, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the multi-item gamma Poisson shrinker (MGPS) and the Bayesian confidence propagation neural network (BCPNN).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 8532 reports of AEs with Tafamidis as the primary suspected drug, Tafamidis-induced AEs were identified as occurring in 27 system organ classes (SOC). A total of 207 Tafamidis-induced AEs were detected which simultaneously complied with the four algorithms. Our analysis also identified new adverse reactions including Hypoacusis, Deafness, and Essential hypertension. The median onset of adverse reactions associated with Tafamidis was 180 days (interquartile range [IQR] 51-419 days).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Tafamidis is a drug that has shown favorable safety and tolerability results in clinical trials. However, a number of adverse reactions associated with Tafamidis have been identified through analysis of the FAERS database. In clinical applications, it is recommended to closely monitor patients' hearing while using Tafamidis. In addition, it is hoped that further experimental and clinical studies will be conducted in the future to understand the mechanism of occurrence between Tafamidis and adverse reactions such as primary hypertension, hyperlipidemia, and height reduction.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Yidan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The First Clinical School of Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sun</LastName><ForeName>Shengzhu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The First Clinical School of Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hongyun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Leiyong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China. zhaoly0703@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China. pengwei0625@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Pharmacol Toxicol</MedlineTA><NlmUniqueID>101590449</NlmUniqueID><ISSNLinking>2050-6511</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8FG9H9D31J</RegistryNumber><NameOfSubstance UI="C547076">tafamidis</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001583">Benzoxazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="Y">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001583" MajorTopicYN="N">Benzoxazoles</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse events</Keyword><Keyword MajorTopicYN="N">Data mining</Keyword><Keyword MajorTopicYN="N">Disproportionality analysis</Keyword><Keyword MajorTopicYN="N">FDA adverse event reporting system</Keyword><Keyword MajorTopicYN="N">Tafamidis</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39334280</ArticleId><ArticleId IdType="pmc">PMC11438280</ArticleId><ArticleId IdType="doi">10.1186/s40360-024-00790-2</ArticleId><ArticleId IdType="pii">10.1186/s40360-024-00790-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED, et al. Systemic amyloidosis from a (aa) to t (attr): a review. J Intern Med. 2021;289(3):268–92. 10.1111/joim.13169.</Citation><ArticleIdList><ArticleId IdType="pubmed">32929754</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, et al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther. 2016;5(1):1–25. 10.1007/s40120-016-0040-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4919130</ArticleId><ArticleId IdType="pubmed">26894299</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton A, Castaño A, Bruno M, Riley S, Schumacher J, Sultan MB, et al. Drug discovery and development in rare diseases: taking a closer look at the tafamidis story. Drug Des Devel Ther. 2021;15:1225–43. 10.2147/DDDT.S289772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7987260</ArticleId><ArticleId IdType="pubmed">33776421</ArticleId></ArticleIdList></Reference><Reference><Citation>Ney S, Gertz RJ, Pennig L, Nies RJ, Holtick U, Völker LA, et al. Multiparametric monitoring of disease progression in contemporary patients with wild-type transthyretin amyloid cardiomyopathy initiating tafamidis treatment. J Clin Med. 2024;13(1). 10.3390/jcm13010284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10779991</ArticleId><ArticleId IdType="pubmed">38202291</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb YN, Deeks ED. Tafamidis: a review in transthyretin amyloidosis with polyneuropathy. Drugs. 2019;79(8):863–74. 10.1007/s40265-019-01129-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">31098895</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–16. 10.1056/NEJMoa1805689.</Citation><ArticleIdList><ArticleId IdType="pubmed">30145929</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber P, Flynn A, Sultan MB, Li H, Rill D, Ebede B, et al. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy. Amyloid. 2019;26(4):203–09. 10.1080/13506129.2019.1643714.</Citation><ArticleIdList><ArticleId IdType="pubmed">31353964</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail. 2022;15(1):e008193. 10.1161/CIRCHEARTFAILURE.120.008193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8763250</ArticleId><ArticleId IdType="pubmed">34923848</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel U, van Stekelenborg J, Dreyfus B, Garg A, Habib M, Hosain R, et al. Investigating overlap in signals from evdas, faers, and vigibase(®). Drug Saf. 2020;43(4):351–62. 10.1007/s40264-019-00899-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105447</ArticleId><ArticleId IdType="pubmed">32020559</ArticleId></ArticleIdList></Reference><Reference><Citation>Montastruc J, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905–08. 10.1111/j.1365-2125.2011.04037.x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244636</ArticleId><ArticleId IdType="pubmed">21658092</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519–23.</Citation><ArticleIdList><ArticleId IdType="pubmed">15317031</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (prrs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–86.</Citation><ArticleIdList><ArticleId IdType="pubmed">11828828</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumouchel W. Bayesian data mining in large frequency tables, with an application to the fda spontaneous reporting system. Am Stat. 1999;53(3):177–90. 10.1080/00031305.1999.10474456.</Citation></Reference><Reference><Citation>Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">9696956</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Zhou L, Shen Y, Zhou Q, Ji Y, Zhu H. Safety assessment of brexpiprazole: real-world adverse event analysis from the faers database. J Affect Disord. 2024;346:223–29. 10.1016/j.jad.2023.11.025.</Citation><ArticleIdList><ArticleId IdType="pubmed">37956832</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang S, Wu Z, Xu L, Wen Q, Zhang X. Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: a pharmacovigilance study based on faers. Front Pharmacol. 2022;13:970066. 10.3389/fphar.2022.970066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9573960</ArticleId><ArticleId IdType="pubmed">36263117</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: thaos (transthyretin amyloid outcome survey). J Am Coll Cardiol. 2016;68(2):161–72. 10.1016/j.jacc.2016.03.596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4940135</ArticleId><ArticleId IdType="pubmed">27386769</ArticleId></ArticleIdList></Reference><Reference><Citation>Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023;118(18):3517–35. 10.1093/cvr/cvac119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9897687</ArticleId><ArticleId IdType="pubmed">35929637</ArticleId></ArticleIdList></Reference><Reference><Citation>Caponetti AG, Rapezzi C, Gagliardi C, Milandri A, Dispenzieri A, Kristen AV, et al. Sex-related risk of cardiac involvement in hereditary transthyretin amyloidosis: insights from thaos. Jacc Heart Fail. 2021;9(10):736–46. 10.1016/j.jchf.2021.05.005.</Citation><ArticleIdList><ArticleId IdType="pubmed">34391735</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell CM, LoRusso S, Dispenzieri A, Kristen AV, Maurer MS, Rapezzi C, et al. Sex differences in wild-type transthyretin amyloidosis: an analysis from the transthyretin amyloidosis outcomes survey (thaos). Cardiol Ther. 2022;11(3):393–405. 10.1007/s40119-022-00265-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9381661</ArticleId><ArticleId IdType="pubmed">35583798</ArticleId></ArticleIdList></Reference><Reference><Citation>Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451–66. 10.1016/j.jacc.2015.09.075.</Citation><ArticleIdList><ArticleId IdType="pubmed">26610878</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Pavía P, Tomé-Esteban MT, Rapezzi C. [Amyloidosis. Also a heart disease]. Rev Esp Cardiol. 2011;64(9):797–808. 10.1016/j.recesp.2011.05.003.</Citation><ArticleIdList><ArticleId IdType="pubmed">21775043</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonçalves I, Alves CH, Quintela T, Baltazar G, Socorro S, Saraiva MJ, et al. Transthyretin is up-regulated by sex hormones in mice liver. Mol Cell Biochem. 2008;317(1–2):137–42. 10.1007/s11010-008-9841-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">18568387</ArticleId></ArticleIdList></Reference><Reference><Citation>Damy T, Costes B, Hagège AA, Donal E, Eicher J, Slama M, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37(23):1826–34. 10.1093/eurheartj/ehv583.</Citation><ArticleIdList><ArticleId IdType="pubmed">26537620</ArticleId></ArticleIdList></Reference><Reference><Citation>Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014–20. 10.1016/j.jacc.2016.06.033.</Citation><ArticleIdList><ArticleId IdType="pubmed">27585505</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North americans. J Am Geriatr Soc. 2012;60(4):765–74. 10.1111/j.1532-5415.2011.03868.x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325376</ArticleId><ArticleId IdType="pubmed">22329529</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133(3):282–90. 10.1161/CIRCULATIONAHA.115.018852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718760</ArticleId><ArticleId IdType="pubmed">26660282</ArticleId></ArticleIdList></Reference><Reference><Citation>Givens RC, Russo C, Green P, Maurer MS. Comparison of cardiac amyloidosis due to wild-type and v122i transthyretin in older adults referred to an academic medical center. Aging Health. 2013;9(2):229–35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3780445</ArticleId><ArticleId IdType="pubmed">24073013</ArticleId></ArticleIdList></Reference><Reference><Citation>Nawarskas JJ, Shephard EA. Tafamidis: a novel treatment for transthyretin amyloid cardiomyopathy. Cardiol Rev. 2020;28(3):156–60. 10.1097/CRD.0000000000000306.</Citation><ArticleIdList><ArticleId IdType="pubmed">32101907</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16–26. 10.1161/CIRCULATIONAHA.118.038169.</Citation><ArticleIdList><ArticleId IdType="pubmed">31109193</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruberg FL, Berk JL. Transthyretin (ttr) cardiac amyloidosis. Circulation. 2012;126(10):1286–300. 10.1161/CIRCULATIONAHA.111.078915.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501197</ArticleId><ArticleId IdType="pubmed">22949539</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukaina M, Rehman S, Waheed M, Shehryar M, Rasool R, Ahmed N, et al. Efficacy of tafamidis in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. Annals Med Surg (2012). 2024;86(1):433–38. 10.1097/MS9.0000000000001482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10783421</ArticleId><ArticleId IdType="pubmed">38222729</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh BM, Bohara N, Gautam K, Basnet M, Kc S, Kc B, et al. A systematic review of tafamidis in patients with transthyretin amyloid cardiomyopathy. Cureus. 2021;13(9):e18221. 10.7759/cureus.18221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8541744</ArticleId><ArticleId IdType="pubmed">34703707</ArticleId></ArticleIdList></Reference><Reference><Citation>Klockars T, Perheentupa T, Dahl HM. In silico analyses of mouse inner-ear transcripts. J Assoc Res Otolaryngology. 2003;4(1):24–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202450</ArticleId><ArticleId IdType="pubmed">12072916</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartier S, Bodez D, Kharoubi M, Guellich A, Canouï-Poitrine F, Chatelin V, et al. Association between hearing loss and hereditary attr amyloidosis. Amyloid. 2019;26(4):234–42. 10.1080/13506129.2019.1663814.</Citation><ArticleIdList><ArticleId IdType="pubmed">31502881</ArticleId></ArticleIdList></Reference><Reference><Citation>Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass L, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24(3):194–204. 10.1080/13506129.2017.1357545.</Citation><ArticleIdList><ArticleId IdType="pubmed">28758793</ArticleId></ArticleIdList></Reference><Reference><Citation>Melse-Boonstra A, Mackenzie I. Iodine deficiency, thyroid function and hearing deficit: a review. Nutr Res Rev. 2013;26(2):110–17. 10.1017/S0954422413000061.</Citation><ArticleIdList><ArticleId IdType="pubmed">23759468</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Wang YJ, Sun X, Zhang N, Li YN, Fan ZM, et al. [Analysis of prognostic factors of low-frequency type of sudden sensorineural hearing loss]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Chin J Otorhinolaryngol Head Neck Surg. 2020;55(7):652–57. 10.3760/cma.j.cn115330-20191212-00756.</Citation><ArticleIdList><ArticleId IdType="pubmed">32668873</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma PM, Trifirò G, Patadia V, Sturkenboom M. Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? Drug Saf. 2013;36(3):183–97. 10.1007/s40264-013-0018-x.</Citation><ArticleIdList><ArticleId IdType="pubmed">23377696</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilar S, Friedman C, Hripcsak G. Detection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media. Brief Bioinform. 2018;19(5):863–77. 10.1093/bib/bbx010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6454455</ArticleId><ArticleId IdType="pubmed">28334070</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi X, Cheng Q, Zhao Y, Zou S, Sun M. A real-world pharmacovigilance study of abaloparatide based on the fda adverse event reporting system (faers). Osteoporos Int. 2023;34(12):2047-58. 10.1007/s00198-023-06877-6</Citation><ArticleIdList><ArticleId IdType="pubmed">37594595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H, Qu Y, Du Z, Zhou Q, Shen Y, Jiang Y, et al. Mining and analysis of adverse event signals of cariprazine based on the real-world data of faers database. J Affect Disord. 2024;347:45–50. 10.1016/j.jad.2023.11.076.</Citation><ArticleIdList><ArticleId IdType="pubmed">37992768</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>